S. Sleep

Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial.

P. Fagone, A. Nienhuis, J. Gray, 2011, Human gene therapy.

Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.

A. Nienhuis, J. Gray, M. Valentine, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Safety and Immunogenicity of an Intranasal Sendai Virus-Based Human Parainfluenza Virus Type 1 Vaccine in 3- to 6-Year-Old Children

J. Allay, C. Russell, P. Freiden, 2015 .

Safety and Immunogenicity of an Intranasal Sendai Virus-Based Human Parainfluenza Virus Type 1 Vaccine in 3- to 6-Year-Old Children

J. Allay, C. Russell, P. Freiden, 2014, Clinical and Vaccine Immunology.

Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

Pratima Chowdary, Savita Rangarajan, Cecilia Rosales, 2011, The New England journal of medicine.

Early Clinical Trial Results Following Administration of a Low Dose of a Novel Self Complementary Adeno-Associated Viral Vector Encoding Human Factor IX In Two Subjects with Severe Hemophilia B

M. Kay, A. Nienhuis, J. Gray, 2010 .

A gene transfer strategy for making bone marrow cells resistant to trimetrexate.

J. Rehg, B. Sorrentino, Raymond L. Blakley, 1996, Blood.

Comparison of the protection of cells from antifolates by transduced human dihydrofolate reductase mutants.

B. Sorrentino, Raymond L. Blakley, H. Spencer, 1997, Human gene therapy.

Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock.

J. Gray, A. Davidoff, A. Nathwani, 2004, Journal of virological methods.

Mutations in the gene for human dihydrofolate reductase: an unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate.

C. Pui, B. Sorrentino, Raymond L. Blakley, 1996, Leukemia.